1. ALLA AKTIER
  2. NYHETER
  3. NEWBURY PHARMACEUTICALS

Newbury Pharmaceuticals

Nyheter Newbury Pharmaceuticals Nyheter alla bolag

Newbury will participate at the RedEye Life Science Day – 24th November 2022

Lars Minor, CEO, Newbury Pharmaceuticals presents at Redeye Life Science Day 2022.

On November 24th at 09:40 AM Newbury CEO, Lars Minor will present and discuss the latest developments in the company at the Redeye Life Science Day. There will be an in-depth interview, called InFocus.

The interview will be broadcasted live at https://www.redeye.se/events/850947/redeye-life-science-day where you also will find our pre-recorded presentation, called Slides and the replay afterwards.

Take your chance to ask questions directly to us via the form on the event page.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Newbury will participate at the RedEye Life Science Day – 24th November 2022

Datum 2022-11-22, kl 08:00
Källa MFN
Bifogade filer
Newbury will participate at the RedEye Life Science Day – 24th November 2022
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.